Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics has initiated the Phase 3 FORZETTO trial for z-rostudirsen in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. The 72-week, placebo-controlled study will enroll approximately 90 participants, with the primary endpoint being rise from floor (RFF) velocity at Week 73.
Key figures
- Drug Name
- z-rostudirsen (DYNE-251)
- Phase Of Trial
- Phase 3
- Trial name
- FORZETTO
- Dosing regimen
- 20 mg/kg every 4 weeks
- Primary endpoint
- Rise from floor (RFF) velocity
- Enrollment target
- 90
- Trial duration weeks
- 72
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.